Invisible antimicrobial glove and hand antiseptic

Information

  • Patent Grant
  • 7488757
  • Patent Number
    7,488,757
  • Date Filed
    Wednesday, March 24, 2004
    20 years ago
  • Date Issued
    Tuesday, February 10, 2009
    15 years ago
Abstract
An alcohol based hand surgical scrub, which includes cationic anti-microbial agent preservatives, cationic polymer film-forming agents and a skin emollient, and provides a long term residual, anti-microbial “invisible glove” on the skin. The composition provides an immediate reduction in bacterial microbes. The polymer system creates an invisible film on the skin following solvent evaporation. This invisible film provides a lasting anti-microbial barrier on the skin which acts to prevent microbial growth.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


The present invention relates to an alcohol-based antiseptic surgical scrub, which leaves an anti-microbial invisible film or “glove” on the hands, following alcohol evaporation.


2. Description of Related Art


Diligent hand washing and the wearing of gloves by healthcare professionals are essential components of effective infection control in the healthcare environment. Healthcare professionals regularly wash their hands and wear gloves to control the spread of bacteria and infection from patient to patient, and to themselves.


Hand washing procedures are performed in several ways and include products such as an ordinary anti-microbial bar soap, skin disinfecting or pre-operative agents or rubbing alcohol. Such procedures and products contain anti-microbial agents such as alcohol, iodine, chlorhexidine digluconate, chloroxylenol, triclosan and hexachlorophenes. Gloving by the healthcare workers is a normal practice in the hospital setting to create a barrier that protects themselves and the patient from transmitted bacteria.


Healthcare workers commonly use scrub brushes impregnated with anti-microbial agents for antiseptic hand washing prior to surgical procedures and other invasive patient care procedures. These impregnated scrub brushes have proven to be an effective method of reducing the spread of infection in the healthcare setting. Anti-microbial solutions are specially designed for use in the scrub brush where the mechanical action of scrubbing with the brush creates a foam or lather. Before performing a surgical procedure, the surgical team uses surgical scrubs to disinfect their hands with such a standardized scrub procedure, usually lasting 5 to 10 minutes, then don sterile gloves before initializing the surgical procedure.


Alcohols, in general, are recognized for their disinfection properties. Rubbing alcohol, containing 70% ethyl alcohol (Formula 23-H) and 30% water, and isopropyl rubbing alcohol, containing 70% isopropyl alcohol and 30% water, are commonly used disinfectants. Alcohol is a potent anti-microbial agent, and, if used with surgical scrub, will cause significant mean log reduction of bacterial counts on the hands of healthcare workers. However, the use of alcohols for surgical scrubs has never become popular in the United States of America, even though the compound has very good properties for immediate reduction of microbial flora on the hands. This may be due to the fact that alcohol is a defatting agent. When applied to the human skin, it can make the skin very dry, often leading to chapped and cracked skin. These characteristics thus often result in difficult and painful sensitivity for the users.


The prior art includes many examples of varying antiseptic skin cleaners and wipes, some of which include alcohol. U.S. Pat. No. 4,678,606 discloses a personal liquid cleaning composition having a primary surfactant selected from the group of anionic, cationic, zwitterionic, amphoteric and semipolar surfactants, an auxiliary surfactant selected from certain ethoxylated aliphatic alcohols and a water-soluble polymeric thickening agent. U.S. Pat. No. 4,374,126 discloses an alcohol insoluble antimicrobial topical lotion including a lower acrylate interpolymer. U.S. Pat. No. 5,512,199 discloses an antimicrobial hand wipe which includes an alcohol. U.S. Pat. No. 6,180,584 is directed to a film forming antimicrobial composition. Notably, this composition is an alcohol-free anti-microbial skin sanitizing composition.


However, none of these prior art products provide the benefits of the presently disclosed surgical scrub composition, which not only includes alcohol, but also provides the desired invisible, anti-microbial long-lasting film on the hands following solvent evaporation.


SUMMARY OF THE INVENTION

The present invention is an alcohol based hand surgical scrub, which includes dual anti-microbial agent preservatives, cationic polymer film-forming agents and provides a long term residual, anti-microbial “invisible glove” on the skin. The composition desirably comprises an alcohol, anti-microbial agent which prevents the growth of bacteria and a polymer system to form a barrier on the skin. The polymer system creates an invisible film on the skin following solvent evaporation. This invisible film provides a lasting anti-microbial barrier on the skin.


The composition desirably includes an alcohol, a positive charged anti-microbial agent, skin emollients and lubricants and a film-forming polymer system. The composition may also include one or both of methyl and propyl parabens and silicone. The anti-microbial agents prevent bacteria from growing back to the baseline of the normal skin flora population. The surgical scrub composition contains chemical ingredients to remove extraneous matter and organisms from the hands. Skin emollients and lubricants are also provided to prevent the defatting effect of the alcohol, thereby eliminating the dry, chapped feeling on the skin. Additional or complimentary anti-microbial agents are preferably included to serve as preservative and persistent active agents. These anti-microbial agents in the composition will improve the anti-microbial characteristics of the formulation and provide a long-term residual activity for the skin. As previously noted, the polymer system is included to create an invisible film after the solvent is evaporated. This invisible film acts as a physical anti-microbial barrier or “glove” to protect the healthcare worker's hands. This film has an anti-microbial effect at least for six hours to prevent and kill the bacteria on the healthcare worker's hands.







DESCRIPTION OF THE PREFERRED EMBODIMENT(S)

This invention may be satisfied by embodiments in many different forms, and is not limited to any specific or preferred embodiments of the invention, which are merely exemplary of the principles of the invention. Various other modifications will be apparent to and readily made by those skilled in the art without departing from the scope and spirit of the invention. The scope of the invention will be measured by the appended claims and their equivalents.


The surgical scrub composition of the present invention includes alcohol, a positive-charged anti-microbial agent, skin emollients and lubricants, and a cationic polymer film-forming thickening agent.


One or more alcohols are utilized in the surgical scrub composition due to alcohol's well known germicidal properties. Alcohols which may be used in the present composition include isopropyl alcohol, ethanol, and n-propanol. In the most preferred embodiment, ethyl alcohol is used. Preferably, alcohol is present in the surgical scrub composition in an amount from about 60 to about 95 weight percent, and most preferably, at about 71 weight percent.


Emollients are utilized in the surgical scrub composition of the present invention to lessen the drying effect of the alcohol on the skin. A preferred emollient is isopropyl palmitate, which is an ester emollient available from Amerchol Corporation of Edison, N.J. When used on the skin, isopropyl palmitate leaves a soft, non-sticky feel to the skin. Isopropyl palmitate is a lipophillic emollient, an oily, fatty substance which is water insoluble. Lanolin and its derivatives are a large group of fatty materials with active emollient properties that can be utilized as emulsifiers or lubricants in the composition.


The preferred embodiment includes glycerin as a hydrophilic emollient and a humectant to maintain the water in equilibrium. Glycerin is available from Spectrum Quality products. Glycerin is a water and alcohol soluble emollient that provides skin conditioning properties to the composition. In another embodiment, propylene glycol may be substituted for glycerin. Preferably, glycerin is present in the surgical scrub composition, by weight percent of the entire composition, in an amount of from about 0.1% to about 5%, and most preferably, about 1.4%.


The surgical scrub composition further includes a silicone fluid. Preferably, the silicone fluid is dimethicone copolyol, cyclomethicone and dimethicone. Most preferably, dimethicone is utilized. Dimethicone 350 is commercially available from General Electric Corporation. Silicone fluids provide good lubricating, aesthetic and occlusive action on the skin. Silicone fluids not only lubricate the skin surface, they also act as a gas barrier to reduce water vapor transmission. Silicone fluids are water and gas insoluble. Preferably, the silicone fluid is present in the surgical scrub composition, by weight percent of the entire composition, in an amount from 0 to about 5%, and most preferably, about 0.03%.


Most hydrocarbons are derived from petrolatum crude by a fractional distillation process. Such hydrocarbons function as emollients due to their ability to lubricate and hold water at the skin surface due to their relative occlusivity. Mineral oil and isopropyl palmitate are included in the most preferred embodiment. Despite its lack of aesthetic properties, petrolatum may be utilized. Alternatively or additionally, lanolin derivatives may be included. Preferably, mineral oil is present in the surgical scrub composition, by weight percent of the entire composition, in an amount from 0 to about 5%, and most preferably, about 0.2%. Preferably, isopropyl palmitate is present in the surgical scrub composition, by weight percent of the entire composition, in an amount from about 0.1% to about 5%, and most preferably about 0.4%.


Preferably, the surgical scrub composition includes about 0.1% to about 5% of an emollient or emollients.


An anti-microbial agent is included in the surgical scrub composition to kill microorganisms and prevent or inhibit their growth and reproduction. In the absence of an antimicrobial agent, microbial flora will grow on the skin following alcohol evaporation. The antimicrobial agents present in the surgical scrub composition are selected to be compatible with the chemical and physical properties of the skin. In addition, the antimicrobial agent should be non-toxic and environmentally friendly.


As previously noted, the alcohol component of the surgical scrub composition is an excellent antimicrobial agent. It also acts as a preservative. However, following application of the surgical scrub composition, the alcohol will evaporate from the skin over time. In the most preferred embodiment, the residue remaining on the skin following alcohol evaporation will include an amount of an antimicrobial agent which also acts as a preservative. Suitable antimicrobial agents which act as preservatives may be selected from the class of phenols including para-chloro-meta-xylenol, bis-biguanides such as chlorhexidine digluconate, chlorhexidine diacetate or quaterium class such as benzethonium chloride, benzalkonium chloride. Chloroxylenol, triclosan, hexachlorophenes, octenidine and quarternary compounds may be included. Hexetidine, germaben II, kathon CG, triclosan are other antimicrobial agents may also be suitable as preservatives. Benzethonium chloride and benalkonium chloride (as hyamine 3500) are available from Lonza Inc., chlorhexidine digluconate is available from Xttrium Laboratories, germaben II is available from Sutton Laboratories. In a most preferred embodiment, benzethonium chloride, chlorhexidine digluconate (20%) and benzelkonium chloride (80%) are present. Preferably, benzethonium chloride is present in the scrub composition, by weight percent of the entire composition, in an amount from about 0.05% to about 5%, and most preferably, about 0.09%. Preferably, chlorhexidine digluconate (20%) is present in the surgical scrub composition, by weight percent of the entire composition, in an amount from about 0.05% to about 5%, and most preferably about 0.45%. Preferably, benzalkonium chloride (80%) is present in the surgical scrub composition, by weight percent of the entire composition, in an amount from 0 to about 5%, and most preferably, about 0.09%. Preferably, the composition includes about 0% to about 5% of an anti-microbial agent.


Methylparaben and propylparaben (both available from Mallinckrodt Chemical Company) are desirably included in the surgical scrub composition as preservatives. These are further desired for their moisturizing and film forming characteristics. Preferably, methylparaben is contained in the surgical scrub composition, by weight percent of the entire composition, in an amount from about 0 to about 5%, and most preferably about 0.03%. Preferably, propylparaben is present in the surgical scrub, by weight percent of the entire composition, in an amount from about 0 to about 5%, and most preferably, about 0.03%. One or both of these compositions are preferably included in the amount of about 0% to about 5% of the surgical scrub composition.


To create the desired residual film of the surgical scrub composition, cationic polymer thickening agents are employed. Thickening agents must be soluble in the alcohol and compatible with cationic ingredients. The cationic polymer thickening agents are preferably present in the surgical scrub composition, by weight percent of the entire composition, in the amount of about 0.1% to about 5%.


Incroquat behenyl TMS is most preferably used as a cationic polymer. It is a strong conditioning agent and an outstanding cationic emulsifier. This composition bonds to the skin due to the skin's negative charge. Incroquat behenyl TMS is a compound of 25% active solution of behenyl trimonium methosulfate in cetearyl alcohol and is available in flaked/pastel form and supplied by Croda Inc. Incroquat CR concentrate is preferably used as an additional cationic polymer. Incroquat CR concentrate is available from Croda Inc. and is comprised of cetearyl alcohol, castor oil and stearalkonium chloride. This composition is a one-part formulating aid. It is a conditioner and self-emulsifier. The desired combination of the incroquat behenyl TMS and incroquat CR concentrate provides a smooth feel to the skin and neutralizes the static charge of the human skin. Preferably, incroquat BTMS is present in the surgical scrub composition, by weight percent of the entire composition, in an amount from about 0.1% to about 5%, and most preferably about 0.4%. Preferably, incroquat CR is present in the surgical scrub composition, by weight percent of the entire composition, in an amount from 0 to about 5%, and most preferably about 0.1%.


Alternative or additional polymers include cellulose, polyvinylpyrolidone and waxes.


The most preferred embodiment of the surgical scrub composition is as follows:















% of Total (w/w)



















1-Docosanol
1.00%



Benzethonium Chloride
0.09%



Chlorhexidine Digluconate, (20%)
0.45%



Dimethicone
0.03%



Ethyl Alcohol
71.00% 



Glycerin
1.40%



Benzalkonium Chloride
0.09%



Incroquat BTMS
0.40%



Incroquat CR
0.10%



Isopropyl Palmitate
0.40%



Mineral Oil
0.20%



Methylparaben
0.03%



PEG-10 Behenyl Ether
1.50%



Propylparaben
0.03%



Purified Water
23.28% 










The most preferred embodiment includes the additional components 1-Docosanol as a moisturizer and film forming substance, PEG-10 behenyl ether as a moisturizer, fragrance and water. Preferably, 1-Docosanol is present in the surgical scrub composition, by weight percent of the entire composition, in an amount from about 0.1% to about 5%, and most preferably about 1%. Preferably, PEG-10 behenyl ether is present in the surgical scrub composition, by weight percent of the entire composition, in an amount from about 0.1% to about 5%, and most preferably about 1.5%. Preferably, purified water is present in the surgical scrub composition, in an amount from about 1% to about 35%, and most preferably about 23%.


The surgical scrub composition does not cause skin irritation or sensitization. Additional advantages of the composition include its compatibility with positive-charged anti-microbial agents such as chlorhexidine digluconate, thus ensuring the effectiveness of the anti-microbial agent or agents. The included skin emollients and lubricants eliminate skin drying or chapping. These compositions counteract the defatting effect of the alcohol.


The surgical scrub composition includes anti-microbial agents, which act as both persistent active agents and suitable preservatives. This composition permits a very small amount of an anti-microbial agent to improve anti-microbial activities and provide long-term residual activity for the skin.


Traditionally, healthcare workers have scrubbed prior to every surgical procedure. An improved method may be to apply water to the skin, perform hand scrubbing at the beginning of the day using a scrub brush and anti-microbial scrub solution, rinsing the anti-microbial scrub solution with water, and then utilization of the composition of the present invention prior to subsequent surgical procedures. A high level of hand antisepsis can be achieved via this method without abrasive scrubbing multiple times a day.


EXAMPLES

The following examples are not intended to limit the scope of the invention, but are only intended to be exemplary in nature.


Standard testing of the most preferred embodiment demonstrates its effectiveness as an antiseptic to provide an immediate reduction of microbes and then to prevent microbial growth back to baseline within a 6-hour period. The immediate log reduction was 2.65 on day 1, 2.92 on day 2 and 3.04 on day 3. The residual effect was a log reduction six hours after hand cleaning of 1.45 on day 1, 1.79 on day 2 and 2.18 on day 3. The residual anti-microbial activity is facilitated by the containment of the anti-microbial agent in the polymer film that is formed. The film forms an invisible “glove” containing an anti-microbial agent. The anti-microbial agent remains on the skin in the film and continues to be bactericidal over extended periods of time. The invisible glove prevents microbes that may be present on the hands of the healthcare worker from infecting a patient and the glove also provides a barrier for microbes infecting the healthcare worker from the patient.


Through testing, the composition has been shown to exceed industry standards. The critical indices for this study were an immediate one (1) log10 reduction in microorganisms on Day 1; an immediate two (2) log10 reduction in microorganisms on Day 2; an immediate three (3) log10 reduction in microorganisms on Day 5; and that microorganism populations from the approximately three (3) hour to three (3) hour and thirty (30) minute AND approximately six (6) hour to six (6) hour and thirty (30) minute samples not return to baseline level. Refer to Table I.









TABLE I







Statistical Summary of the Log10 Recovery Values of Most Preferred Embodiment

















95% Confidence
Log10 Reduction
TFM (1994) Required


Sample
Sample Size
Mean
Standard Deviation
Interval
from Baseline
Log10 Reduction





Baseline
36
6.01
0.40
5.88 to 6.15
N/A



Day 1, Immediate
12
3.36
0.68
2.93 to 3.79
2.65
1


Day 1, 3 Hour
12
4.08
0.99
3.45 to 4.71
1.93
No return to baseline


Day 1, 6 Hour
12
4.56
0.68
4.13 to 4.99
1.45
No return to baseline


Day 2, Immediate
11
3.09
0.53
2.74 to 3.45
2.92
2


Day 2, 3 Hour
11
3.73
0.90
3.12 to 4.34
2.28
No return to baseline


Day 2, 6 Hour
12
4.22
0.81
3.70 to 4.73
1.79
No return to baseline


Day 5, Immediate
10
2.97
0.47
2.63 to 3.31
3.04
3


Day 5, 3 Hour
11
3.50
0.61
3.09 to 3.91
2.51
No return to baseline


Day 5, 6 Hour
11
3.83
1.01
3.15 to 4.51
2.18
No return to baseline









The most preferred embodiment was also tested in conjunction with a standard hand scrub utilizing a brush impregnated with an anti-microbial agent. The composition was applied to the hands of the test subjects one-half hour following the standard scrub. Test results showed an increased log reduction of microbes when the scrubbing and the preferred composition were used together. Log reductions of microbes were 3.66 for Day 1, 3.98 for Day 2, and 3.81 for Day 3. Residual activity was also increased with log reductions after six hours of 2.31 for Day 1, 3.52 for Day 2 and 3.70 for Day 3. Use of the preferred composition in conjunction with a standard scrub exceeded industry standards for anti-microbial compositions. Refer to Table II and FIG. 1.


BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a graphical presentation of the log10 reductions from baseline for the preferred formula and BD E-Z Scrub™ [BD Catalog #371073] plus the most preferred embodiment.









TABLE II







Statistical Summary of the Log10 Recovery Values Using BD E-Z Scrub ™


Catalog #371073 Plus Most Preferred Embodiment

















95% Confidence
Log10 Reduction
TFM (1994) Required


Sample
Sample Size
Mean
Standard Deviation
Interval
from Baseline
Log10 Reduction





Baseline
38
6.10
0.38
5.97 to 6.22
N/A



Day 1, Immediate
12
2.88
0.46
2.15 to 2.73
3.66
1


Day 1, 3 Hour
13
3.13
0.79
2.65 to 3.60
2.97
No return to baseline


Day 1, 6 Hour
13
3.79
0.88
3.26 to 4.32
2.31


Day 2, Immediate
12
2.12
0.35
1.90 to 2.34
3.98
2


Day 2, 3 Hour
12
2.58
0.93
1.99 to 3.17
3.52
No return to baseline


Day 2, 6 Hour
12
2.58
0.66
2.16 to 3.00
3.52


Day 5, Immediate
10
2.29
0.37
2.02 to 2.55
3.81
3


Day 5, 3 Hour
10
2.28
0.32
2.05 to 2.51
3.82
No return to baseline


Day 5, 6 Hour
12
2.40
0.49
2.09 to 2.71
3.70








Claims
  • 1. A surgical scrub composition comprising, in weight percent of the total composition: (a) from about 0.1% to about 5% of 1-docosanol;(b) from about 0.05% to about 5% of chlorhexidine digluconate;(c) from about 60% to about 95% of alcohol;(d) from about 0.1% to about 5% of glycerin;(e) from about 0.1% to about 5% of a 25% active solution of behenyl trimethyl ammonium methosulfate in cetearyl alcohol;(f) from about 0.1% to about 5% of isopropyl palmitate;(g) from about 0.03% to about 5% of a preservative selected from the group consisting of methylparaben and propylparaben; and(h) from about 1% to about 35% of purified water.
  • 2. A method of using a surgical scrub composition for hand antisepsis comprising: (a) applying a cleansing liquid to the skin;(b) scrubbing the skin with an anti-microbial scrub solution;(c) rinsing the anti-microbial scrub solution from the skin; and(d) applying an effective amount of a surgical scrub composition according to claim 1.
Parent Case Info

This application is 371 of PCT/US04/009009, filed 24 Mar. 2004, which claims priority from provisional application No. 60/457,054, filed 24 Mar. 2003.

PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/US2004/009009 3/24/2004 WO 00 7/24/2006
Publishing Document Publishing Date Country Kind
WO2004/084973 10/7/2004 WO A
US Referenced Citations (174)
Number Name Date Kind
4009714 Hammer Mar 1977 A
4066556 Vaillancourt Jan 1978 A
4294594 Sloane, Jr. et al. Oct 1981 A
4309992 Dodak et al. Jan 1982 A
4311587 Nose et al. Jan 1982 A
4374126 Cardarelli et al. Feb 1983 A
4416772 Sato et al. Nov 1983 A
4560382 Isono Dec 1985 A
4568366 Frederick et al. Feb 1986 A
4678606 Akhter et al. Jul 1987 A
4695382 Cronin Sep 1987 A
4702829 Polaschegg et al. Oct 1987 A
4714556 Ambrus et al. Dec 1987 A
4738668 Bellotti et al. Apr 1988 A
4787974 Ambrus et al. Nov 1988 A
4861485 Fecondini Aug 1989 A
4895566 Lee Jan 1990 A
5053339 Patel Oct 1991 A
5093235 Williams et al. Mar 1992 A
5217493 Raad et al. Jun 1993 A
5252222 Matkovich et al. Oct 1993 A
5312813 Costerton et al. May 1994 A
5366505 Farber Nov 1994 A
5512199 Khan et al. Apr 1996 A
5530102 Gristina et al. Jun 1996 A
5554147 Batich et al. Sep 1996 A
5556760 Nakamura et al. Sep 1996 A
5638812 Turner Jun 1997 A
5645824 Lim et al. Jul 1997 A
5716406 Farber Feb 1998 A
5723132 Tseng et al. Mar 1998 A
5788687 Batich et al. Aug 1998 A
5798115 Santerre et al. Aug 1998 A
5817063 Turnbull Oct 1998 A
5855896 Lim et al. Jan 1999 A
5906834 Tseng May 1999 A
5935094 Zupkas Aug 1999 A
6017334 Rawls Jan 2000 A
6022551 Jampani et al. Feb 2000 A
6022748 Charych et al. Feb 2000 A
6048337 Svedman Apr 2000 A
6080423 Charych et al. Jun 2000 A
6106287 Yates Aug 2000 A
6132765 DiCosmo et al. Oct 2000 A
6159007 Sorensen Dec 2000 A
6171496 Patil Jan 2001 B1
6180135 Charych et al. Jan 2001 B1
6180584 Sawan et al. Jan 2001 B1
6228393 DiCosmo et al. May 2001 B1
6257265 Brunner et al. Jul 2001 B1
6259074 Brunner et al. Jul 2001 B1
6277652 Jo et al. Aug 2001 B1
6282444 Kroll et al. Aug 2001 B1
6306422 Batich et al. Oct 2001 B1
6306598 Charych et al. Oct 2001 B1
6350251 Prosl et al. Feb 2002 B1
6391001 Graham et al. May 2002 B1
6395561 Charych et al. May 2002 B1
6399853 Roe et al. Jun 2002 B1
6423219 Chandler Jul 2002 B1
6428491 Weiss Aug 2002 B1
6436885 Biedermann et al. Aug 2002 B2
6451748 Taylor et al. Sep 2002 B1
6468649 Zhong Oct 2002 B1
6471689 Joseph et al. Oct 2002 B1
6475434 Darouiche Nov 2002 B1
6475516 DiCosmo et al. Nov 2002 B2
6479727 Roe Nov 2002 B1
6501002 Roe et al. Dec 2002 B1
6540915 Patil Apr 2003 B2
6562295 Neuberger May 2003 B1
6579539 Lawson et al. Jun 2003 B2
6660484 Charych et al. Dec 2003 B2
6666842 Sakai Dec 2003 B1
6699391 Baldridge et al. Mar 2004 B2
6713660 Roe et al. Mar 2004 B1
6719907 Collins et al. Apr 2004 B2
6719991 Darouiche et al. Apr 2004 B2
6723350 Burrell et al. Apr 2004 B2
6723689 Hoang et al. Apr 2004 B1
6731971 Evans, III et al. May 2004 B2
6758971 Haight Jul 2004 B1
6758975 Peabody et al. Jul 2004 B2
6776912 Baurmeister Aug 2004 B2
6783713 Tremblay et al. Aug 2004 B2
6800200 Bassett et al. Oct 2004 B2
6803363 Polaschegg Oct 2004 B2
6814085 Brattesani et al. Nov 2004 B2
6814724 Taylor Nov 2004 B2
6835713 Montelaro et al. Dec 2004 B2
6838005 Tepper et al. Jan 2005 B2
6843784 Modak et al. Jan 2005 B2
6844028 Mao et al. Jan 2005 B2
6849463 Santini, Jr. et al. Feb 2005 B2
6858139 Taylor Feb 2005 B2
6887270 Miller et al. May 2005 B2
6887847 Montelaro et al. May 2005 B2
6921390 Bucay-Couto et al. Jul 2005 B2
20010010016 Modak Jul 2001 A1
20010049975 Howard et al. Dec 2001 A1
20020009436 Doyle et al. Jan 2002 A1
20020015716 Jampani et al. Feb 2002 A1
20020037260 Budny et al. Mar 2002 A1
20020051812 DiCosmo et al. May 2002 A1
20020064858 Yacoby-Zeevi May 2002 A1
20020066702 Liu Jun 2002 A1
20020068093 Trogolo et al. Jun 2002 A1
20020091424 Biel Jul 2002 A1
20020102405 Chapman et al. Aug 2002 A1
20020123787 Weiss Sep 2002 A1
20030018306 Bucay-Couto et al. Jan 2003 A1
20030065292 Darouiche et al. Apr 2003 A1
20030068667 Olson et al. Apr 2003 A1
20030105143 Ammenodola et al. Jun 2003 A1
20030134783 Harshey et al. Jul 2003 A1
20030153983 Miller et al. Aug 2003 A1
20030175812 Reppy et al. Sep 2003 A1
20030176367 Cali et al. Sep 2003 A1
20030176848 Gibson et al. Sep 2003 A1
20030206875 Budny et al. Nov 2003 A1
20030215433 Kokai-Kun et al. Nov 2003 A1
20030224032 Read et al. Dec 2003 A1
20030229065 Levy et al. Dec 2003 A1
20040044299 Utsugi Mar 2004 A1
20040106912 Rosinskaya et al. Jun 2004 A1
20040109852 Xu Jun 2004 A1
20040115721 Mao et al. Jun 2004 A1
20040116845 Darouiche et al. Jun 2004 A1
20040116896 Massengale Jun 2004 A1
20040122511 Mangiardi et al. Jun 2004 A1
20040126897 Prince et al. Jul 2004 A1
20040132164 Doyle et al. Jul 2004 A1
20040132217 Prince et al. Jul 2004 A1
20040172000 Roe et al. Sep 2004 A1
20040180829 Bassler et al. Sep 2004 A1
20040188351 Thiele et al. Sep 2004 A1
20040230162 Tan Nov 2004 A1
20040235914 Ammendola et al. Nov 2004 A1
20040249441 Miller et al. Dec 2004 A1
20040254545 Rider et al. Dec 2004 A1
20050008671 Antwerp Jan 2005 A1
20050010158 Brugger et al. Jan 2005 A1
20050020960 Brugger et al. Jan 2005 A1
20050020961 Burbank et al. Jan 2005 A1
20050037498 Ribi Feb 2005 A1
20050038376 Zumeris et al. Feb 2005 A1
20050038498 Dubrow et al. Feb 2005 A1
20050048124 Sarangapani Mar 2005 A1
20050049181 Madhyastha Mar 2005 A1
20050059731 Albrecht et al. Mar 2005 A1
20050085775 Ostfeld et al. Apr 2005 A1
20050085777 Tan Apr 2005 A1
20050090785 Tan Apr 2005 A1
20050095351 Zumeris et al. May 2005 A1
20050100937 Holmes May 2005 A1
20050101841 Kaylor et al. May 2005 A9
20050118239 Sabesan Jun 2005 A1
20050124678 Levy et al. Jun 2005 A1
20050131332 Kelly et al. Jun 2005 A1
20050131356 Ash et al. Jun 2005 A1
20050137536 Gonnelli Jun 2005 A1
20050142622 Sanders et al. Jun 2005 A1
20050143286 Singh et al. Jun 2005 A1
20050154448 Cully et al. Jul 2005 A1
20050158253 Budny et al. Jul 2005 A1
20050161859 Miller et al. Jul 2005 A1
20050171501 Kelly Aug 2005 A1
20050192590 Feeley et al. Sep 2005 A1
20050199245 Brennan Sep 2005 A1
20050209547 Burbank et al. Sep 2005 A1
20050220837 Disegi et al. Oct 2005 A1
20050221072 Dubrow et al. Oct 2005 A1
20050233950 Madhyastha Oct 2005 A1
20050256502 DiMatteo et al. Nov 2005 A1
Related Publications (1)
Number Date Country
20060263323 A1 Nov 2006 US
Provisional Applications (1)
Number Date Country
60457054 Mar 2003 US